These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1900284)

  • 1. On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator.
    Lijnen HR; Van Hoef B; Collen D
    J Biol Chem; 1991 Mar; 266(7):4041-4. PubMed ID: 1900284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
    Lijnen HR; De Cock F; Collen D
    Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural determinants of the noncatalytic chain of tissue-type plasminogen activator that modulate its association rate with plasminogen activator inhibitor-1.
    de Serrano VS; Castellino FJ
    J Biol Chem; 1990 Jun; 265(18):10473-8. PubMed ID: 2113057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.
    Declerck PJ; Lijnen HR; Verstreken M; Moreau H; Collen D
    Blood; 1990 May; 75(9):1794-800. PubMed ID: 1691934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of tissue-type plasminogen activator with human endothelial cell monolayers. Characterization of the high affinity interaction with plasminogen activator inhibitor-1.
    Russell ME; Quertermous T; Declerck PJ; Collen D; Haber E; Homcy CJ
    J Biol Chem; 1990 Feb; 265(5):2569-75. PubMed ID: 2105930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and secretion of plasminogen activator inhibitor 1 by human endothelial cells in vitro. Effect of active site mutagenized tissue-type plasminogen activator.
    Bartha K; Declerck PJ; Moreau H; Nelles L; Collen D
    J Biol Chem; 1991 Jan; 266(2):792-7. PubMed ID: 1898737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
    Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
    Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a chimaeric plasminogen activator obtained by insertion of the second kringle structure of tissue-type plasminogen activator (amino acids 173 through 262) between residues Asp130 and Ser139 of urokinase-type plasminogen activator.
    Lijnen HR; Piérard L; Reff ME; Gheysen D
    Thromb Res; 1988 Dec; 52(5):431-41. PubMed ID: 3146822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.
    Li XK; Lijnen HR; Nelles L; Van Hoef B; Stassen JM; Collen D
    Blood; 1992 Jan; 79(2):417-29. PubMed ID: 1730087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.
    Keijer J; Ehrlich HJ; Linders M; Preissner KT; Pannekoek H
    J Biol Chem; 1991 Jun; 266(16):10700-7. PubMed ID: 1709939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.
    Morton PA; Owensby DA; Wun TC; Billadello JJ; Schwartz AL
    J Biol Chem; 1990 Aug; 265(24):14093-9. PubMed ID: 2167306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of wild-type and catalytically inactive mutant forms of tissue-type plasminogen activator with human umbilical vein endothelial cell monolayers.
    Ramakrishnan V; Sinicropi DV; Dere R; Darbonne WC; Bechtol KB; Baker JB
    J Biol Chem; 1990 Feb; 265(5):2755-62. PubMed ID: 2105933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
    Lijnen HR; Dewerchin M; De Cock F; Collen D
    Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase.
    Hajjar KA; Hamel NM
    J Biol Chem; 1990 Feb; 265(5):2908-16. PubMed ID: 2154465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin.
    Dewerchin M; Lijnen HR; Van Hoef B; De Cock F; Collen D
    Eur J Biochem; 1989 Oct; 185(1):141-9. PubMed ID: 2530085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.
    Morton PA; Owensby DA; Sobel BE; Schwartz AL
    J Biol Chem; 1989 May; 264(13):7228-35. PubMed ID: 2540181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
    Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
    J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue-type plasminogen activator and urokinase: differences in the reaction pattern with the active-site titrant 4-methylumbelliferyl-p-guanidinobenzoate hydrochloride.
    Geiger M; Binder BR
    Biochim Biophys Acta; 1987 Mar; 912(1):34-40. PubMed ID: 3103686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu).
    Lijnen HR; Van Hoef B; Nelles L; Collen D
    J Biol Chem; 1990 Mar; 265(9):5232-6. PubMed ID: 1969415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.